Comparative Pharmacology
Head-to-head clinical analysis: DRAX EXAMETAZIME versus DRAXIMAGE MDP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAX EXAMETAZIME versus DRAXIMAGE MDP 25.
DRAX EXAMETAZIME vs DRAXIMAGE MDP-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAX EXAMETAZIME is a diagnostic radiopharmaceutical composed of technetium-99m (Tc-99m) labeled to exametazime (hexamethylpropyleneamine oxime, HMPAO). It passively diffuses across the blood-brain barrier and is rapidly converted to a hydrophilic complex, which is trapped in brain tissue. Distribution is proportional to regional cerebral blood flow, allowing SPECT imaging of cerebral perfusion.
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
Adult: 5-20 mCi (185-740 MBq) administered intravenously as a single dose for brain imaging; dose is based on patient weight and imaging protocol.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
None Documented
None Documented
Terminal half-life is 6-8 hours; clinical context: allows for daily dosing in imaging studies.
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Renal: 50-65% unchanged; fecal: 35-50% as metabolites; total renal elimination accounts for ~70% of dose, with 30% undergoing biliary excretion.
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical